Answers are grounded in this paper and cite their sources.
studied the combination of chemotherapy (gemcitabine and nab-paclitaxel) with either an anti-PD1 (nivolumab) or an anti-CD40 (sotigalimab) antibody in metastatic pancreatic cancer. They showed clinical benefit in individuals with unique biomarkers for each treatment combination.
No takes yet. Share an insight, caveat, or question.
Cornelis J.M. Melief (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: